Agreement sharpens AstraZeneca’s focus on priority medicines in Respiratory & Immunology portfolio (PRESS RELEASE) CAMBRIDGE, 1-Nov-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced it sold the global rights of its chronic obstructive … Read the full press release →
Posted in Business, Healthcare, Management, News, Pharma & Biotech
Tagged Aclidinium bromide, Almirall S.A., Alvesco, AstraZeneca, biopharmaceutical, Bretaris, Chronic obstructive pulmonary disease, COPD, Covis Pharma, Covis Pharma Group, Duaklir, Eklira, formoterol, Genuair, Genuair device, global rights, inhaler, LABA, LAMA, long-acting beta2-agonist, long-acting muscarinic antagonist, medicines, Omnaris, Pressair, respiratory medicines, rights, Tudorza, Zetonna